TY - JOUR
T1 - A systematic approach for successful PCSK9 inhibitor prescribing in clinical practice
AU - Knickelbine, Thomas
AU - Jia, Lori
AU - White, Susan K.
AU - Garberich, Ross F.
AU - Oberembt, Sandra J.
AU - Wills, Samantha
AU - Miedema, Michael D.
AU - Brilakis, Emmanouil S.
N1 - Funding Information:
Authors contribution: Conception and design of study was performed by TK, SKW, RFG, SJO, SW, MDM, and ESB. Acquisition, analysis, and interpretation of data were performed by TK, LJ, SKW, and RFG. Manuscript drafting and revision was performed by TK, LJ, and SKW. All authors provided final approval of the submitted version. Conflict of interest: none. This study was sponsored by the Minneapolis Heart Institute Foundation
Funding Information:
This study was sponsored by the Minneapolis Heart Institute Foundation
Publisher Copyright:
© 2019 National Lipid Association
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Background: Despite patient and provider interest, the use of PCSK9i therapy remains limited in clinical practice. High annual listed prices have created intense payer scrutiny and frequent health plan denials, with national approval rates in the range of 30% to 40%. Objective: Our goal was to validate the strategies for increasing PCSK9i approval rates and to present a framework for successful PCSK9i prescribing in clinical practice. Methods: In Sept 2015, a systematic team-based approach was developed and implemented at our institution. The approach centered on a preventive team of 3 senior staff cardiologists, 1 nurse practitioner, 1 physician assistant, 1 care coordinator, 1 pharmacist, and 1 pharmacy technician. The team was responsible for gathering and compiling the required documents to support an approval, as well as collaborating with the in-house pharmacy to complete PA and appeals processes. Results: In the total study population, 141 (71.9%)were approved for PCSK9i therapy at first submission and 55 (28.1%)were rejected. Of those initially rejected, 48 (85.7%)appealed and all 48 who appealed (100.0%)were ultimately approved. The final coverage decision was 189 (96.4%)approved and 7 (3.6%)rejected. Conclusion: Our study highlights the presence of modifiable barriers in the PCSK9i approval process. Given the crucial role of health care teams in overcoming these modifiable barriers, we developed a simple stepwise algorithm for navigating the PCSK9i approval process. Our algorithm can help relieve busy providers of heavy administrative burdens and facilitate greater accuracy, standardization, and efficiency in documentation.
AB - Background: Despite patient and provider interest, the use of PCSK9i therapy remains limited in clinical practice. High annual listed prices have created intense payer scrutiny and frequent health plan denials, with national approval rates in the range of 30% to 40%. Objective: Our goal was to validate the strategies for increasing PCSK9i approval rates and to present a framework for successful PCSK9i prescribing in clinical practice. Methods: In Sept 2015, a systematic team-based approach was developed and implemented at our institution. The approach centered on a preventive team of 3 senior staff cardiologists, 1 nurse practitioner, 1 physician assistant, 1 care coordinator, 1 pharmacist, and 1 pharmacy technician. The team was responsible for gathering and compiling the required documents to support an approval, as well as collaborating with the in-house pharmacy to complete PA and appeals processes. Results: In the total study population, 141 (71.9%)were approved for PCSK9i therapy at first submission and 55 (28.1%)were rejected. Of those initially rejected, 48 (85.7%)appealed and all 48 who appealed (100.0%)were ultimately approved. The final coverage decision was 189 (96.4%)approved and 7 (3.6%)rejected. Conclusion: Our study highlights the presence of modifiable barriers in the PCSK9i approval process. Given the crucial role of health care teams in overcoming these modifiable barriers, we developed a simple stepwise algorithm for navigating the PCSK9i approval process. Our algorithm can help relieve busy providers of heavy administrative burdens and facilitate greater accuracy, standardization, and efficiency in documentation.
KW - Alirocumab (Praluent)
KW - Atherosclerotic cardiovascular disease (ASCVD)
KW - Evolocumab (Repatha)
KW - Familial hypercholesterolemia (FH)
KW - Low-density lipoprotein cholesterol (LDL-C)
KW - Prior authorization
UR - http://www.scopus.com/inward/record.url?scp=85061092065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061092065&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2019.01.005
DO - 10.1016/j.jacl.2019.01.005
M3 - Article
C2 - 30745203
AN - SCOPUS:85061092065
SN - 1933-2874
VL - 13
SP - 265
EP - 271
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 2
ER -